Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline
The Global Coagulation Disorders Market is Forecast to Slow Down Due to a Series of Patent Expiries
In 2010, the global coagulation disorders market was estimated to be worth $5.6 billion, representing a compound annual growth rate (CAGR) of 6.7% between 2002 and 2010. By 2017, the global coagulation disorders market is estimated to reach $8.3 billion, indicating a CAGR of 5.7% between 2010 and 2017. The major reason for the reduced growth rate is the expected decline in the annual cost of treating coagulation disorders after 2010.
The global coagulation disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes most of the top selling blockbuster drugs in the hemophilia disease markets. The major drugs that are set to lose patent protection between 2010 and 2017 include NovoSeven (2010), ReFacto (2010), BeneFIX (2011) and Kogenate FS in the US (2014).
While the current coagulation disorders pipeline does offer some promising products, the revenues generated from these products are not expected to completely offset the revenue lost due to the patent expiries. Therefore, the overall market growth of the global coagulation disorders market is expected to slow down in the future.
The Global Coagulation Disorders Pipeline is Dominated by Early-Stage Development Products
The current coagulation disorders market scenario demands substantial output from the research and development (R&D) departments of pharmaceutical companies. With a series of patent expiries expected in the next seven years, disease indications such as hemophilia A and hemophilia B are set to lose billions of dollars of revenue from the market as a result.
The current pharmaceutical pipeline for coagulation disorders does provide some promising drugs. However, the drugs are not expected to completely replace the revenue losses experienced due to the patent expiry of the current blockbuster drugs, such as Kogenate FS, NovoSeven, BeneFIX and others.
The hemophilia pipeline is largely dominated by early stage development projects. In the hemophilia pipeline, early stage development, which includes the discovery, preclinical and Phase I stages, accounts for 54% of the total projects. The preclinical stage in the hemophilia pipeline accounts for approximately 34% of the total R&D programs, the largest of all the stages. This is followed by Phase II programs, which account for approximately 24% of the total R&D programs, while Phase III programs account for 16%. The discovery stage accounts for 4% of the pipeline, while NDA filed projects form 2%. The primary focus of the pipeline has remained finding a cure for hemophilia A, which is approximately five times as common as hemophilia B.
The current coagulation disorders pipeline focuses on three major indications: hemophilia A, hemophilia B and von Willebrand disease. Approximately 89% of the current coagulation disorders pipeline concentrates on hemophilia A and hemophilia B as its major indications. About 54% of the coagulation disorders pipeline is in the early stages of development for hemophilia.
About 34% of the total projects for hemophilia A and hemophilia B are in the preclinical stage, which suggests that the future hemophilia market can expect some novel drugs. The vWD disease market is comparatively smaller than the markets for hemophilia A and hemophilia B. With less market opportunities available, pharmaceutical companies do not make these indications their top priorities. vWD accounts for 11% of the current coagulation disorders pipeline, with a total of eight projects.
Large Number of Licensing Deals in the Coagulation Disorders Market Focused on the US and Europe
A large number of licensing deals in the coagulation disorders market are focused on the US and Europe. The US witnessed the most licensing activity with 41%, followed by deals focused on the US, Europe, Asia-Pacific, Middle East and Africa at 31%. Deals specific to Europe accounted for 17% of the total agreements, while Asia-Pacific witnessed 4% of the licensing activity at a global level.
GBI Research, the leading business intelligence provider, has released its latest research, “Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global coagulation disorders market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Market size, annual cost of therapy and treatment usage patterns are forecast until 2017 for the key geographies, as well as the leading therapeutic segments which includes hemophilia A, hemophilia B and von Willebrand Disease. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global coagulation disorders market.
GBI Research’s analysis indicates that the global coagulation disorders market has been one of the fastest growing markets from 2002-2010. However, the market growth is expected to slow down in the future due to various restraints, such as the expiry of key drug patents across all disease segments, generic substitution, biosimilar penetration, and the decreasing annual cost of disease treatment in major markets such as the US, Japan and the top five countries in Europe. Nevertheless, the global coagulation disorders market is still forecast to grow at a moderate rate over the next seven years.
To purchase the report or for further information go to:
About GBI Research
GBI Research is a leading business information company providing global business information reports and services.
Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research.
The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GBI Research delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GBI Research can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.
Have Your Say
Rate this feature and give us your feedback in the comments section below